SPECIAL NOTICE
A -- Gene Silencing Method
- Notice Date
- 5/13/2003
- Notice Type
- Special Notice
- Contracting Office
- Department of Energy, Lawrence Livermore National Laboratory (DOE Contractor), Industrial Partnerships & Commercialization, 7000 East Avenue L-795, Livermore, CA, 94550
- ZIP Code
- 94550
- Solicitation Number
- Reference-Number-FBO000022-03
- Response Due
- 6/13/2003
- Archive Date
- 6/16/2003
- Point of Contact
- Connie Pitcock, Administration, Phone 925-422-1072, Fax 925-423-8988,
- E-Mail Address
-
pitcock1@llnl.gov
- Description
- LAWRENCE LIVERMORE NATIONAL LABORATORY SEEKS LICENSEES TO COMMERCIALIZE GENE SILENCING METHOD Announcement: Lawrence Livermore National Laboratory (LLNL), operated by the University of California under contract with the U.S. Department of Energy (DOE), is seeking one or more industrial partners to commercialize LLNL's gene silencing method. Scientists at LLNL have invented a novel method to silence gene expressing by using a novel short interfering nucleic acid molecule. Because of its unique composition, the novel molecule can exert superior gene silencing functions than short interfering RNA (siRNA or RNAi) molecules. For example, it is well known that siRNA (or RNAi) cannot silence a gene without a transfection mean or an internally expressed vector. It has also been widely accepted that siRNA (or RNAi) cannot silence gene expression in bacteria. However, scientists at LLNL have successfully used the novel molecule to silence gene expression in bacterial and mammalian cells. Uniquely, the novel molecule can silence genes without using any transfection medium; simply adding it to the growth media is sufficient to induce gene silencing. Furthermore, the novel molecule is more potent than siRNA (or RNAi), both in duration and magnitude. Experiments at LLNL proved that under the same conditions, the novel molecule silenced a target gene for more than two weeks while siRNA (or RNAi) silenced the same gene for about two days. These experiments also proved that a relatively lower concentration of the novel molecule is needed than siRNA (or RNAi) to achieve the same level of gene silencing. With these special characteristics, the novel molecule is an ideal candidate for new antibiotics, antiviral agents, fungicides, and therapeutics for diseases relating to undesirable gene expression. It will also serve as a powerful tool to study gene expression and functions. LLNL has taken necessary procedures to protect the invention. A patent is pending for the invention. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's gne silencing method should provide a written statement of interest including a commercialization plan and a description of corporate capabilities relevant to commercializing the technology. Written responses should be directed to: Lawrence Livermore National Laboratory Industrial Partnerships and Commercialization P.O. Box 808, L-795 Livermore, CA 94551-0808 Attention: FBO000022-03. Please provide your written statement within thirty (30) days from the date this announcement is published to ensure consideration of your interest in LLNL's subject gene silencing technology.
- Record
- SN00322965-W 20030515/030513213328 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |